Q1 EPS Estimate for Nektar Therapeutics Boosted by Analyst

Nektar Therapeutics (NASDAQ:NKTR) – William Blair lifted their Q1 2025 earnings per share estimates for shares of Nektar Therapeutics in a research report issued on Thursday, March 13th. William Blair analyst A. Hsieh now forecasts that the biopharmaceutical company will earn ($0.19) per share for the quarter, up from their prior estimate of ($0.22). William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share. William Blair also issued estimates for Nektar Therapeutics’ Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.75) EPS, FY2026 earnings at ($0.87) EPS and FY2027 earnings at ($0.88) EPS.

A number of other equities analysts have also recently issued reports on NKTR. B. Riley initiated coverage on Nektar Therapeutics in a report on Wednesday, January 8th. They issued a “buy” rating and a $4.00 target price for the company. Oppenheimer raised Nektar Therapeutics from a “market perform” rating to an “outperform” rating and set a $6.00 price target for the company in a report on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $6.50 price target on shares of Nektar Therapeutics in a report on Thursday. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $4.92.

Nektar Therapeutics Trading Up 10.0 %

Shares of NKTR opened at $0.90 on Monday. Nektar Therapeutics has a 1 year low of $0.65 and a 1 year high of $1.93. The stock has a 50 day simple moving average of $0.88 and a 200-day simple moving average of $1.08. The stock has a market cap of $165.42 million, a PE ratio of -1.07 and a beta of 0.65.

Nektar Therapeutics (NASDAQ:NKTR) last issued its earnings results on Wednesday, March 12th. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.33. Nektar Therapeutics had a negative return on equity of 173.28% and a negative net margin of 180.70%. The business had revenue of $29.18 million during the quarter, compared to analysts’ expectations of $36.65 million.

Insider Buying and Selling at Nektar Therapeutics

In other Nektar Therapeutics news, insider Jonathan Zalevsky sold 51,115 shares of the stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $0.94, for a total value of $48,048.10. Following the transaction, the insider now directly owns 326,904 shares in the company, valued at approximately $307,289.76. This trade represents a 13.52 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Howard W. Robin sold 46,995 shares of the stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $1.01, for a total value of $47,464.95. Following the completion of the transaction, the chief executive officer now owns 1,195,710 shares in the company, valued at $1,207,667.10. The trade was a 3.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 165,586 shares of company stock worth $159,990. Insiders own 3.71% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Eventide Asset Management LLC boosted its position in shares of Nektar Therapeutics by 24.8% in the 3rd quarter. Eventide Asset Management LLC now owns 9,400,000 shares of the biopharmaceutical company’s stock worth $12,220,000 after purchasing an additional 1,870,904 shares during the last quarter. Nantahala Capital Management LLC boosted its position in shares of Nektar Therapeutics by 90.0% in the 4th quarter. Nantahala Capital Management LLC now owns 7,810,000 shares of the biopharmaceutical company’s stock worth $7,263,000 after purchasing an additional 3,700,000 shares during the last quarter. Woodline Partners LP boosted its position in shares of Nektar Therapeutics by 187.3% in the 4th quarter. Woodline Partners LP now owns 4,974,512 shares of the biopharmaceutical company’s stock worth $4,626,000 after purchasing an additional 3,242,841 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Nektar Therapeutics by 17.5% during the fourth quarter. Renaissance Technologies LLC now owns 3,910,786 shares of the biopharmaceutical company’s stock worth $3,637,000 after acquiring an additional 583,153 shares in the last quarter. Finally, State Street Corp lifted its holdings in Nektar Therapeutics by 11.9% during the third quarter. State Street Corp now owns 3,345,733 shares of the biopharmaceutical company’s stock worth $4,349,000 after acquiring an additional 355,759 shares in the last quarter. 75.88% of the stock is currently owned by institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.